Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Summary

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

Timeline

Start

2024-03-04

Primary completion

2026-02-06

Completion

2026-02-06

Outcome

Outcome not reported

Stopped (Business): “Following Completion of dose escalation, the study has been discontinued as part of the Company's strategic priorization of its pipeline.”

Drugs

Indications